CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 129 enrolled / 129 target
Drug / intervention
Anamorelin Hydrochloride +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03035409
NCT03035409Phase 2ActiveUpdate Overdue (1.1/mo)Completion was 78mo ago
CompareCT.gov

Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center·interventional·Posted Jan 30, 2017·Updated Jun 18, 2026

In Brief

A Phase 2 clinical trial evaluating Anamorelin Hydrochloride, Exercise Intervention, and 4 other interventions for Advanced Malignant Solid Neoplasm and 5 related conditions. Active but no longer recruiting, targeting 129 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This phase II trial studies how well anamorelin hydrochloride, physical activity, and nutritional counseling work in decreasing cancer-related fatigue in patients with incurable solid tumors that have spread to other parts of the body or have come back. Anamorelin hydrochloride, physical activity, and nutritional counseling may help to decrease cancer-related fatigue in patients with solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Neoplasm, C-Reactive Protein Measurement, Cancer Fatigue, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Weight Loss
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
201720182019202020212022202320242025202620272028
First PostedJan 30, 2017
Enrollment StartFeb 8, 2017
Primary CompletionDec 27, 2019
Study CompletionFeb 28, 2028
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 9.4 years ago

Arms & Interventions

Supportive Care (anamorelin, physical activity, counseling)experimental

Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.

Drug: Anamorelin HydrochlorideBehavioral: Exercise InterventionOther: Laboratory Biomarker AnalysisOther: Nutritional AssessmentOther: Quality-of-Life AssessmentOther: Questionnaire Administration

Interventions

Anamorelin Hydrochloridedrug

Given PO

Exercise Interventionbehavioral

Undergo physical activity

Laboratory Biomarker Analysisother

Correlative studies

Nutritional Assessmentother

Undergo nutritional counseling

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies